Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
 
Currency:  € $ £
Discounted Reports
MARKET RESEARCH SECTOR IN FOCUS
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare
Textiles
MARKET REPORT DETAIL

Infectious Vaccines Partnering Terms and Agreements

Enquire | Email | Print

Published Date: Dec, 2013
Format: PDF
No of Pages: 950

 
 
Select pricing :
Change Currency: € EURO | $ USD | £ GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

The Infectious Vaccines Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What are the precise rights granted or optioned?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of infectious vaccines dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading infectious vaccines deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the big biotech companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of infectious vaccines partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in infectious vaccines partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectious vaccines technologies and products.

Report scope

Infectious Vaccines Partnering Agreements is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.

Infectious Vaccines Partnering Agreements includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2007
Analysis of infectious vaccines deal structure
Access to headline, upfront, milestone and royalty data
Access to over 700 infectious vaccines deal records
The leading infectious vaccines deals by value since 2007
Includes adjuvant deals and alliances since 2007

In Infectious Vaccines Partnering Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of infectious vaccines deal trends since 2007
• Access infectious vaccines deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between infectious vaccines partner companies
• Comprehensive access to over 700 links to actual infectious vaccines deals entered into by the world’s biopharma companies
• Indepth review of infectious vaccines deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner infectious vaccines opportunities
• Uncover companies actively partnering infectious vaccines opportunities



Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in infectives vaccine dealmaking

2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Bigp harma Infectious Vaccines dealmaking activity
2.4. Most active in Infectious Vaccines partnering
2.5. Infectious Vaccines partnering by deal type
2.6. Infectious Vaccines partnering by stage of development
2.7. Infectious Vaccines partnering by infectives indication
2.8. Infectious Vaccines partnering by vaccine and adjuvant indication
2.9. Disclosed deal terms for Infectious Vaccines partnering
2.9.1 Infectious Vaccines partnering headline values
2.9.2 Infectious Vaccines deal upfront payments
2.9.3 Infectious Vaccines deal milestone payments
2.9.4 Infectious Vaccines royalty rates
2.10. The anatomy of Infectious Vaccines partnering
2.10. The anatomy of a Infectious Vaccines deal
2.10.a. Case study 1: Gilead Sciences, GlobeImmune- Oct 24 2011
2.10.b. Case study 2: Astellas, Vical: July 14, 2011

Chapter 3 – Leading Infectious Vaccines deals

3.1. Introduction
3.2. Top Infectious Vaccines deals by value

Chapter 4 – Big pharma Infectious Vaccines deals

4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Big pharma Infectious Vaccines partnering company profiles
Abbott
Astellas
AstraZeneca
Baxter International
Bayer
CSL
Daiichi Sankyo
Eisai
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Mitsubishi Tanabe
Novartis
Pfizer
Purdue
Sanofi
Shionogi
Takeda


Chapter 5 – Big biotech infectives vaccine deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech infectives vaccine partnering company profiles
Bavarian Nordic
Cangene
Emergent BioSolutions

Chapter 6 – Infectious Vaccines dealmaking directory

6.1. Introduction
6.2. Company A-Z
3M
A*STAR Agency for Science, Technology and Research
A*STAR Bioprocessing Technology Institute
A*STAR Singapore Immunology Network
Aaron Diamond AIDS Research Center
Abbott Laboratories
Aberystwyth University
Academia Sinica
Acambis
Accelovance
ACE BioSciences
Achaogen
ADImmune
Aduro BioTech
Advanced BioNutrition
Advanced BioScience Laboratories
Advanced Immunization Technologies (ADITEC)
Advaxis
Aeras Global TB Vaccine Foundation
AFFiRiS
Agenus Bio
Ajanta Pharma
Akshaya Bio
Albany Medical College
Albert Einstein College of Medicine
Aldevron
Alexis Biotech
Algonomics
ALK-Abello
Allied Healthcare Group
Alnylam Pharmaceuticals
Alphavax
Althea Technologies
AltraVax
American Type Culture Collection (ATCC)
AmVac
Amyris Biotechnologies
AnC Bio
AnGes MG
Antelope Valley Biologics
Antigen Discovery
Antigen Express
Antigenics
Antitope
Apogee Biotechnology
Apotex
Archimedes Development
Archimedes Pharma
Arecor
Argos Therapeutics
Ariad Pharmaceuticals
AriaVax
Arizona State University
Ark Therapeutics
Artepharm Co
Artepharm Global
Artes Biotechnology
Astellas
Astellas Pharma US
AstraZeneca
Astrogenetix
Atreca
Australian Centre for Vaccine Development
Australian National University
AVANT Immunotherapeutics
Avecia Biologics
AVI Pharma
Avid Bioservices
Avimex
Barr Pharmaceuticals
Battelle
Bavarian Nordic
Baxter Healthcare
Bayer
Beijing Health Bureau
Beijing Tiantan Biological Products
Beth Israel Deaconess Medical Center
Biken
Bill and Melinda Gates Foundation
BinnoPharm
Bio-Manguinhos
BioAlliance Pharma
BioCryst Pharmaceuticals
BioDiem
Biofactura
Bioject Medical Technologies
Biolik Biopharmaceutical
Biological E
Biomedical Advanced Research and Development Authority
BiondVax
Bioniche Life Sciences
Bionor Pharma
BioPharm Services
BioReliance
Biota
Biotechnology and Biological Sciences Research Council (BBSRC)
BioVeris
BioVest
Birmex
Boryung Pharmaceutical
Brigham Young University
Butantan Institute
Cadila Pharmaceuticals
Cambridge BioStability
Capsulation NanoScience
Carrington Laboratories
Case Western Reserve University
Catherex
Catholic University of America
Celldex Therapeutics
Cellectis Bioresearch
Centegen
Center for Disease Control and Prevention
Centers for Disease Control and Prevention
Centre National de Recherche et de Formation sur le Paludisme
Centro de Investigacion y Asistencia Tecnologica y Diseno del Estado de Jalisco
Centrovet
Centrovet Laboratories
Ceva Sante Animale
Cevec Pharmaceuticals
Changchun BCHT Biotechnology
ChemRar High-Tech Center
Chengdu Institute of Biological Products
Cheyney University
Children's Hospital of Philadelphia
China Centre for Disease Control
China National Biotech Group (CNBG)
Chinese Federal Government
Chongqing Zhifei Biological Products
ChronTech Pharma
Chumakov Institute of Poliomyelitis and Viral Encephalitides
ClinTec International
Cobra Biologics
Coley Pharmaceutical Group
Colorado Institute for Drug, Device and Diagnostic Development
Compass Biotechnologies
Corgenix Medical
CPL Biologicals
Crossbeta Biosciences
Crucell
Crucible International Biotechnologies
CSIRO
CSL
CSL Biotherapies
CureVac
Cytodyn
CytoGenix
Cytos
Daiichi Pharmaceutical
Daiichi Sankyo
Dalton Pharma Services
Dana-Farber Cancer Institute
Danish Defence
Dartmouth College
DBV Technologies
Defence Research and Development Canada
Defense Advanced Research Projects Agency
Defense Threat Reduction Agency
Defyrus
Delphi Genetics
Delsite
Department of Defense
Department of Health and Human Services
Department of Homeland Security
Diagnostic Hybrids
DOR BioPharma
Drexel University
DRI Capital
Drugs for Neglected Diseases Initiative
Duke-NUS Graduate Medical School Singapore
Duke University
Duke University Medical Center
Dynavax Technologies
DynPort Vaccine Company
Eden Biodesign
Eisai
Elanco
Emcure Pharmaceuticals
EMD Millipore
Emergent BioSolutions
Emergent Product Development
Emory University
Encorium Group
Endobiologics
EnWave
Epic Bio
EpiCept
Epitopix
Erasmus University Medical Center
Esteve
European Commission
Evolutec
Evolva
Exploit Technologies
ExpreS2ion Biotechnologies
Fabentech
Fina Biosolutions
FIT Biotech
FluGen
Food and Drug Administration (FDA)
Formatech
Fort Dodge Animal Health
Fourth Military Medical University
Fraunhofer USA
Fraunhofer USA Center for Molecular Biotechnology
French National Institute for Agricultural Research
French National Research Agency
G-Con
Gador
Gamma Vaccines
GE Healthcare
Geneart
Generex Biotechnology
GeneThera
Genetic Immunity
Genocea Biosciences
GenomIdea
GenPhar
GenVec
GeoVax
German Cancer Research Center
Gilead Sciences
GlaxoSmithKline
GlaxoSmithKline Biologicals
Glide
GlobeImmune
GlycoMimetics
Glycosensors and Diagnostics
GlycoVaxyn
GNI
Government of Canada
Government of China
Government of India
Government of Japan
Government of United Kingdom
Green Cross
Harbin Pharmaceutical Group
Harrisvaccines
Harvard Medical School
Harvard University
Hawaii Biotech
Health Protection Agency (HPA)
Heat Biologics
Helmholtz Centre for Infection Research
HemispheRx Biopharma
Henderson Morley
Henry Schein
HIV Vaccine Trials Network (HVTN)
Hollister-Stier Labs
Hunan Biopharmaceutical
IBio
IBioPharma
Ichor Medical Systems
Icon Genetics
ID Biomedical
IHI
IHI Plant Engineering Corporation
ImmBio
Immune Design
ImmuneRegen BioSciences
Immunomedics
Immunovaccine
ImmunoVaccine Technologies
Imperial Innovations
Imugene
In Cell Art
Inclinix
Infectious Disease Research Institute (IDRI)
Inovio Biomedical
Inovio Pharmaceuticals
Inserm
Institut Pasteur
Institute for Medical Microbiology, Immunology and Hygiene (IMMIH)
Institute for OneWorld Health
Integrated BioTherapeutics
Intercell
International AIDS Vaccine Initiative
International Center for Genetic Engineering and Biotechnology
International Vaccine Institute (IVI)
Intervet
Inviragen
InVitria
Iomai
Ippox Foundation
IQ Products
IrsiCaixa AIDS Research Institute
Isconova
Istituto Superiore di Sanita
Italian Government
Janssen Pharmaceutica NV
Janssen Pharmaceutical
Jantibody Therapeutics
Japan Government
Jenner Institute
Jiangsu Walvax
Johns Hopkins University
Johnson & Johnson
JSC Binnopharm
Juvaris BioTherapeutics
Kaketsuken
Karolinska Institute
Kirin Pharma
Kitasato Daiichi Sankyo Vaccine
Kitasato Institute
Kyoto Biken
Kyowa Hakko Kirin
La Jolla Institute for Allergy & Immunology
Lallemand Pharma Europe
Lebanese-Canadian Hospital
Lentigen
LG Life Sciences
LigoCyte Pharmaceuticals
Lipotek
Lipoxen
Liquidia Technologies
Lohmann Animal Health
Lonza
Lucigen
Mahidol University
Maryland Technology Development Corporation
Massachusetts Biologic Laboratories
Massachusetts General Hospital
MassBiologics
Max-Planck
Max Planck Institute for Dynamics of Complex Technical Systems
Maxcyte
Maxygen
Mayo Clinic
Medicago
Medicine in Need
Medicines for Malaria Venture
MediGene
MedImmune
Medison Pharma
Mellow Hope Bio Chem
Merck and Co
Merial
Meridian Bioscience
Merix Bioscience
Metabolon
Microbix Biosystems
Military HIV Research Program (MHRP)
Ministry of Health of Brazil
Mitsubishi Tanabe Pharma
Mologen
Monash University
MonoSol Rx
Mount Sinai School of Medicine
MPI Research
MSD Wellcome Trust Hilleman Laboratories
Mucosis
Mymetics
Nabi Biopharmaceuticals
NanoBio
Nanotherapeutics
NanoViricides
Narvac
NASA
NasVax
National Cancer Institute
National Health and Medical Research Council
National Healthcare Services (NHS)
National Institute of Allergy and Infectious Diseases
National Institute of Infectious Diseases
National Institute of Nanotechnology
National Institute on Drug Abuse (NIDA)
National Institutes of Health
National Microbiology Laboratory
National Research Council Canada
National Research Council of Canada
National University of Singapore
Naval Medical Research Center
Navy Medical Research Centre
Netherlands Vaccine Institute
Neugenesis
New York Medical College
Niigata TLO/NBRP/KUTLO-NITT
Ninebio
NineSigma
Nobilon
Noguchi Memorial Institute for Medical Research
Novartis
Novartis Vaccines
Novation
Novavax
Novozymes
Numerate
Nuron Biotech
NYU Langone Medical Center
Omnia Biologics
Omnivest
Opal Therapeutics
OPKO Health
Opsona Therapeutics
Ortho-McNeil-Janssen Pharmaceuticals
Ortho-McNeil
OSEO
Oswaldo Cruz Foundation
Oswaldo Cruz Foundation (Fiocruz)
Oxford- Emergent Tuberculosis Consortium
Oxford BioMedica
PacificGMP
Paladin Labs
Pan-Provincial Vaccine Enterprise
Pan American Health Organization
Paragon Bioservices
Parenteral Biotech
PATH (Appropriate Technology in Health)
PATH Malaria Vaccine Initiative
PaxVax
PECET
Pediatric Dengue Vaccine Initiative
Pennsylvania Department of Health
Pepscan Therapeutics
PepTcell
Peptimmune
PeptiVir
Pevion
Pfenex
Pfizer
Pfizer Animal Health
PharmaJet
Pharmaq
PharmAthene
Pharmexa
Pharmsynthez
Philip Morris Products
Ploughshare Innovations
PPD
Presido Pharmaceuticals
Prevtec microbia
ProBioGen
Profectus Biosciences
Prokarium
Protein Potential
Protein Sciences
Protherics
PsiOxus Therapeutics
Purdue Research Foundation
Qiagen
Radboud University Nijmegen Medical Centre
Ragon Institute
Rapid Micro Biosystems
Ratio
Receptor Logic
ReGenX Biosciences
Replikun Biotech
Research Council of Norway
Rhapsody Biologics
Riboxx Pharmaceuticals
Romark Laboratories
ROVI Pharmaceuticals
Royalty Pharma
Sabin Vaccine Institute
SAIC-Frederick
Sanaria
Sanofi-Aventis
Sanofi-Pasteur
Sanofi
Sanofi Pasteur KK
Saskatchewan Research Council
Scancell
Scarab Genomics
Schering-Plough
Science Applications International Corporation (SAIC)
SciGen
Scripps Research Institute
Seattle Biomed
Select Vaccines
Selecta Biosciences
Sentry BioPharma
Sepragen
Serum Institute of India
Shanghai Centers for Disease Control and Prevention
Shantha Biotechnics
Shenzhen Neptunus Interlong Bio-Technique
Shionogi
SIGA Technologies
Sinobiomed
Sinovac Beijing
Sinovac Biotech
SK Chemicals
Skystar Biopharmaceutical
Soligenix
Sorrento Therapeutics
Southern Research Institute
SRI International
Stabilitech
Statens Serum Institute
Stellar Biotechnologies
Sumagen
Swiss Tropical and Public Health Institute
Symphony Dynamo
Synthetic Genomics Vaccines
Syntiron
Synvolux Therapeutics
Taiwan Cobia
Takeda Pharmaceutical
Talecris Biotherapeutics
TapImmune
Tasly Pharmaceuticals
TB Alliance
TD Vaccines
Technology Strategy Board
Telormedix
Temasek Life Sciences
Terumo
Tetragenetics
The International AIDS Vaccine Initiative
The Qater Foundation
Tianjin CanSino Biotechnology
TNO Pharma
Top Institute Pharma
Torii Pharmaceutical
Transgene
Trius Therapeutics
Tuberculosis Vaccine Initiative
Tulane University
UK Government
UK HIV Vaccine Consortium
UMN Pharma
Uniformed Services University of the Health Sciences
UniQuest
United Biomedical
United Nations
United Nations Children Fund
United States Agency for International Development
Universidad de los Andes
University of Adelaide
University of Birmingham
University of British Columbia
University of California, Davis
University of California
University of Canberra
University of Chicago
University of Colorado
University of Connecticut
University of Copenhagen
University of Guelph
University of Kansas
University of Maryland
University of Maryland Biotechnology Institute
University of Maryland School of Medicine
University of Massachusetts
University of Massachusetts Medical School
University of Medicine and Dentistry of New Jersey
University of Melbourne
University of Miami Miller School of Medicine
University of Michigan
University of Minnesota
University of New Mexico
University of North Carolina
University of Oxford
University of Pennsylvania
University of Pittsburgh
University of Queensland
University of Rochester
University of Texas
University of Texas at El Paso
University of Texas Medical Branch
University of Utah
University of Washington
University of Wisconsin
US Army
US Army Medical Research Institute of Infectious Diseases
US Government
VABIOTECH
Vaccine Technologies
Vakzine Projekt Management
Vandalia Research
VaxDesign
Vaxent
VaxGen
Vaxin
VaxInnate
Vet Cure Pharma
VGX Pharmaceuticals
Vibalogics
Vical
Vichem Chemie
Victorian College of Pharmacy
Viral Genetics
Virbac
ViRexx
Virginia Commonwealth University
Virogen
Virosome Biologicals
ViroStatics
VitamFero
Vivaldi Biosciences
Vivalis
Wageningen University
Walter and Eliza Hall Institute
Walter Reed Army Institute of Research
Wellcome Trust
Wistar Institute
Wittycell
World Bank
World Health Organization
Wyeth
Xcellerex
Xiamen University
Xoma
XTL Biopharmaceuticals
Yokohama City University
Ypsomed
Yunnan Walvax Biotech
6.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
6.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Manufacturing - OEM
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
5.5. By Infectious Vaccines area
Infectives
5.6. By related technology
Adjuvant
Vaccines

Chapter 7 –Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Therapy Reports

Table of Figures

Figure 1: Infectives vaccine partnering since 2007
Figure 2: Bigpharma – top 50 – infectives vaccine deals 2007 to 2013
Figure 3: Bigpharma infectives vaccine deal frequency – 2007 to 2013
Figure 4: Active cancer vaccine dealmaking activity– 2007 to 2013
Figure 5: Infectives vaccine partnering by deal type since 2007
Figure 6: Infectives vaccine partnering by stage of development since 2007
Figure 7: Infectives vaccine partnering by infectives target since 2007
Figure 8: Infectives vaccine partnering by specific technology target since 2007
Figure 9: Infectives vaccine deals with a headline value – by stage of development
Figure 10: Infectives vaccine deal headline value distribution, US$million – discovery stage
Figure 11: Infectives vaccine deal deal headline value distribution, US$million – preclinical stage
Figure 12: Infectives vaccine deal deal headline value distribution, US$million – phase I stage
Figure 13: Infectives vaccine deal headline value distribution, US$million – phase II stage
Figure 14: Infectives vaccine deal deal headline value distribution, US$million – phase III stage
Figure 15: Infectives vaccine deal deal headline value distribution, US$million – marketed stage
Figure 16: Infectives vaccine deal headline value – median value by stage of development
Figure 17: Infectives vaccine deals with upfront payment values – by stage of development
Figure 18: Infectives vaccine deal upfront payment value distribution, US$million – discovery stage
Figure 19: Infectives vaccine deal upfront payment value distribution, US$million – preclinical stage
Figure 20: Infectives vaccine deal upfront payment value distribution, US$million – phase I stage
Figure 21: Infectives vaccine deal upfront payment value distribution, US$million – phase II stage
Figure 22: Infectives vaccine deal upfront payment value distribution, US$million – phase III stage
Figure 23: Infectives vaccine deal upfront payment value distribution, US$million – marketed stage
Figure 24: Cancer vaccine deal upfront payment value – median value by stage of development
Figure 25: Infectives vaccine deals with milestone payment – by stage of development
Figure 26: Infectives vaccine deal milestone payment value distribution, US$million – discovery stage
Figure 27: Infectives vaccine deal milestone payment value distribution, US$million – preclinical stage
Figure 28: Infectives vaccine deal milestone payment value distribution, US$million – phase I stage
Figure 29: Infectives vaccine deal milestone payment value distribution, US$million – phase II stage
Figure 30: Infectives vaccine deal milestone payment value distribution, US$million – phase III stage
Figure 31: Infectives vaccine deal milestone payment value distribution, US$million – marketed stage
Figure 32: Infectives vaccine deals with royalty rates-by stage of development
Figure 33: Infectives vaccine deal royalty rate payment value distribution, US$million – discovery stage
Figure 34: Infectives vaccine deal royalty rate payment value distribution, US$million – preclinical stage
Figure 35: Infectives vaccine deal royalty rate payment value distribution, US$million – phase I stage
Figure 36: Infectives vaccine deal royalty rate payment value distribution, US$million – phase II stage
Figure 37: Infectives vaccine deal royalty rate payment value distribution, US$million – phase III stage
Figure 38: Infectives vaccine deal royalty rate payment value distribution, US$million – marketed stage
Figure 39: Infectives vaccine deal royalty rate payment value – median value by stage of development
Figure 40: Components of the typical infectives vaccine deal structure
Figure 41: Top infectives vaccine deals by value since 2007
Figure 42: Online partnering resources
Figure 43: Forthcoming partnering events
Figure 44: Deal type definitions



Related Reports:  

 

Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.

 

Top Go to top of the page

product id: 106606, price: INR 120745, CurrentPartnering

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
E-mail: info@bharatbook.com
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
 
GPlus
About Trust Online